¢¸
  • [°£È£] ¸¸¼º½ÅºÎÀü°ü·Ã Àú³ÎÇؼ®   (1 ÆäÀÌÁö)
    1

  • [°£È£] ¸¸¼º½ÅºÎÀü°ü·Ã Àú³ÎÇؼ®   (2 ÆäÀÌÁö)
    2

  • [°£È£] ¸¸¼º½ÅºÎÀü°ü·Ã Àú³ÎÇؼ®   (3 ÆäÀÌÁö)
    3

  • [°£È£] ¸¸¼º½ÅºÎÀü°ü·Ã Àú³ÎÇؼ®   (4 ÆäÀÌÁö)
    4

  • [°£È£] ¸¸¼º½ÅºÎÀü°ü·Ã Àú³ÎÇؼ®   (5 ÆäÀÌÁö)
    5


  • º» ¹®¼­ÀÇ
    ¹Ì¸®º¸±â´Â
    5 Pg ±îÁö¸¸
    °¡´ÉÇÕ´Ï´Ù.
¢º
Ŭ¸¯ : ´õ Å©°Ôº¸±â
  • [°£È£] ¸¸¼º½ÅºÎÀü°ü·Ã Àú³ÎÇؼ®   (1 ÆäÀÌÁö)
    1

  • [°£È£] ¸¸¼º½ÅºÎÀü°ü·Ã Àú³ÎÇؼ®   (2 ÆäÀÌÁö)
    2

  • [°£È£] ¸¸¼º½ÅºÎÀü°ü·Ã Àú³ÎÇؼ®   (3 ÆäÀÌÁö)
    3

  • [°£È£] ¸¸¼º½ÅºÎÀü°ü·Ã Àú³ÎÇؼ®   (4 ÆäÀÌÁö)
    4

  • [°£È£] ¸¸¼º½ÅºÎÀü°ü·Ã Àú³ÎÇؼ®   (5 ÆäÀÌÁö)
    5



  • º» ¹®¼­ÀÇ
    (Å« À̹ÌÁö)
    ¹Ì¸®º¸±â´Â
    5 Page ±îÁö¸¸
    °¡´ÉÇÕ´Ï´Ù.
´õºíŬ¸¯ : ´Ý±â
X ´Ý±â
µå·¡±× : Á¿ìÀ̵¿

[°£È£] ¸¸¼º½ÅºÎÀü°ü·Ã Àú³ÎÇؼ®

·¹Æ÷Æ® > ÀǾຸ°Ç ÀÎ ¼â ¹Ù·Î°¡±âÀúÀå
Áñ°Üã±â
Å°º¸µå¸¦ ´­·¯ÁÖ¼¼¿ä
( Ctrl + D )
¸µÅ©º¹»ç
Ŭ¸³º¸µå¿¡ º¹»ç µÇ¾ú½À´Ï´Ù.
¿øÇÏ´Â °÷¿¡ ºÙÇô³Ö±â Çϼ¼¿ä
( Ctrl + V )
ÆÄÀÏ : [°£È£] ¸¸¼º½ÅºÎÀü°ü·Ã Àú³ÎÇؼ®.hwp   [Size : 19 Kbyte ]
ºÐ·®   5 Page
°¡°Ý  1,000 ¿ø

Ä«Ä«¿À ID·Î
´Ù¿î ¹Þ±â
±¸±Û ID·Î
´Ù¿î ¹Þ±â
ÆäÀ̽ººÏ ID·Î
´Ù¿î ¹Þ±â


¸ñÂ÷/Â÷·Ê
`¿ø¹®`
Á¦¸ñ: Antithrombotic Prophylaxis and Therapy in Renal
Failure...Hartmann B, Czock D, Keller F: Drug therapy in patients with
chronic renal failure. Dtsch Arztebl Int 2xxx; 107(37): 647-56.
-ÀúÀÚ: Kienitz, Carsten; Rosin, Ludger; Paar, W. Dieter
-¼Ò¼Ó±â°ü: Sanofi-Aventis Deutschland GmbH Potsdamer Str. 8 10785 Berlin,
Germany
-¼ö·Ï ÃâÆǹ°: Deutsches Aerzteblatt International (DTSCH AERZTEBL INT),
2/18/2xxx; 108(7): 112-113. (2p)
-ÃâÆǹ° À¯Çü: Journal Article ...
º»¹®/³»¿ë

`¿ø¹®`

Á¦¸ñ: Antithrombotic Prophylaxis and Therapy in Renal
Failure...Hartmann B, Czock D, Keller F: Drug therapy in patients with
chronic renal failure. Dtsch Arztebl Int 2xxx; 107(37): 647-56.

-ÀúÀÚ: Kienitz, Carsten; Rosin, Ludger; Paar, W. Dieter
-¼Ò¼Ó±â°ü: Sanofi-Aventis Deutschland GmbH Potsdamer Str. 8 10785 Berlin,
Germany
-¼ö·Ï ÃâÆǹ°: Deutsches Aerzteblatt International (DTSCH AERZTEBL INT),
2/18/2xxx; 108(7): 112-113. (2p)
-ÃâÆǹ° À¯Çü: Journal Article - commentary, letter
-¾ð¾î: English
-ÁÖ¿ä ÁÖÁ¦¸í: Heparin, Low-Molecular-Weight Therapeutic Use
Kidney Failure, Chronic
-ºÎÂ÷ ÁÖÁ¦¸í: Heparin, Low-Molecular-Weight Administration and Dosage;
Thromboembolism Risk Factors
-Àú³Î ÇÏÀ§ÁýÇÕ: Biomedical; Blind Peer Reviewed; Continental Europe;
Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed

The authors postulate a `deep compartment` for enoxaparin. This is
su¡¦(»ý·«)


ÀÚ·áÁ¤º¸
ID : dldm****
Regist : 2018-06-15
Update : 2018-06-15
FileNo : 18084443

Àå¹Ù±¸´Ï

¿¬°ü°Ë»ö(#)
°£È£   ¸¸¼º½ÅºÎÀü°ü·Ã   Àú³ÎÇؼ®  


ȸ»ç¼Ò°³ | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ | °í°´¼¾ÅÍ ¤Ó olle@olleSoft.co.kr
¿Ã·¹¼ÒÇÁÆ® | »ç¾÷ÀÚ : 408-04-51642 ¤Ó ±¤ÁÖ±¤¿ª½Ã ±¤»ê±¸ ¹«Áø´ë·Î 326-6, 201È£ | äÈñÁØ | Åë½Å : ±¤»ê0561È£
Copyright¨Ï ¿Ã·¹¼ÒÇÁÆ® All rights reserved | Tel.070-8744-9518
ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æħ ¤Ó °í°´¼¾ÅÍ ¤Ó olle@olleSoft.co.kr
¿Ã·¹¼ÒÇÁÆ® | »ç¾÷ÀÚ : 408-04-51642 | Tel.070-8744-9518